Blue Rush: One Company Leads the Race to Own Marine Genetic Sequences

Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.

Written byRuth Williams
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

ISTOCK, BOYMONSTERMany marine organisms have evolved to exist in some of the most extreme conditions on earth—high pressure, cold temperatures, hot thermal vents, or low light. As such, their genomes are a source of largely untapped information that could be useful for a wide variety of potential biomedical and industrial technologies. But who are the early prospectors mining these marine genetic resources (MGRs) and who stands to benefit from them? While the answer to the second question is not yet clear, a report in Science Advances today (June 6) suggests that, with 47 percent of all registered MGR patents, German chemical manufacturer BASF is by far the biggest fish in these speculative seas.

“This is an important paper as it shines a light on who owns genetic sequence patents in the international ocean . . . and illustrates how easy it is for resources in the deep ocean to be removed without notice,” Lisa Levin of the Scripps Institution of Oceanography who was not involved in the research writes in an email to The Scientist.

Anyone can go out there and get anything they want and do anything they want with it.—Robert Blasiak,
Stockholm University

“If marine genetic resources are patented on a first come, first served basis, without obligation to share benefits,” Levin continues, “then the majority of the countries of the world without the ability to sample, study and develop marine genetic resources will lose out ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • ruth williams

    Ruth is a freelance journalist. Before freelancing, Ruth was a news editor for the Journal of Cell Biology in New York and an assistant editor for Nature Reviews Neuroscience in London. Prior to that, she was a bona fide pipette-wielding, test tube–shaking, lab coat–shirking research scientist. She has a PhD in genetics from King’s College London, and was a postdoc in stem cell biology at Imperial College London. Today she lives and writes in Connecticut.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies